Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

Also called NCT04100434

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04100434
Other papers using this trial's data
  • Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes - exploratory analysis of the EMSIACS trial Scientific reports, 2025-11-27 DOI, PubMed 41309899, PMC12660667 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04100434. Randomized; double masking; primary purpose treatment. Start 2021-01-01 (anticipated); primary completion 2022-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome
Acronym
EMSIACS
Condition
Acute Coronary Syndrome
Condition
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
Intervention (Drug)
Evolocumab
Lead sponsor
Tianjin Chest Hospital (class: other)

Record details

Record id
cardio:ct-nct04100434
Content hash
9c5dbf1caca42fb0d464e025bbea1475ce11a32f235ab0481a203b1aac5321ae